Claire A. Scott
Queen Mary University of London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Claire A. Scott.
Biochimica et Biophysica Acta | 2012
Claire A. Scott; Daniel Tattersall; Edel A. O'Toole; David P. Kelsell
The expression of multiple connexin (Cx) types in the epidermis, their differential expression during wound closure and the association of skin pathology with specific Cx gene mutations, are indicative of important functions for Cxs in the skin. In this review, we focus on the role of Cx proteins in the epidermis and during wound healing and discuss mutations in Cx genes which cause skin disease. This article is part of a Special Issue entitled: The Communicating junctions, composition, structure and characteristics.
The Journal of Membrane Biology | 2007
Y. K. Stella Man; Caroline Trolove; Daniel Tattersall; Anna C. Thomas; Annie Papakonstantinopoulou; Drashnika Patel; Claire A. Scott; Jiehan Chong; Daniel J. Jagger; Edel A. O’Toole; Harshad Navsaria; Michael A. Curtis; David P. Kelsell
A large proportion of recessive nonsyndromic hearing loss is due to mutations in the GJB2 gene encoding connexin 26 (Cx26), a component of a gap junction. Within different ethnic groups there are specific common recessive mutations, each with a relatively high carrier frequency, suggesting the possibility of heterozygous advantage. Carriers of the R143W GJB2 allele, the most prevalent in the African population, present with a thicker epidermis than noncarriers. In this study, we show that (R143W)Cx26-expressing keratinocytes form a significantly thicker epidermis in an organotypic coculture skin model. In addition, we show increased migration of cells expressing (R143W)Cx26 compared to (WT)Cx26-overexpressing cells. We also demonstrate that cells expressing (R143W)Cx26 are significantly less susceptible to cellular invasion by the enteric pathogen Shigella flexneri than (WT)Cx26-expressing cells. These in vitro studies suggest an advantageous effect of (R143W)Cx26 in epithelial cells.
Biochemical Journal | 2011
Claire A. Scott; David P. Kelsell
Cx (connexin) proteins are components of gap junctions which are aqueous pores that allow intercellular exchange of ions and small molecules. Mutations in Cx genes are linked to a range of human disorders. In the present review we discuss mutations in β-Cx genes encoding Cx26, Cx30, Cx30.3 and Cx31 which lead to skin disease and deafness. Functional studies with Cx proteins have given insights into disease-associated mechanisms and non-gap junctional roles for Cx proteins.
Human Molecular Genetics | 2009
Daniel Tattersall; Claire A. Scott; Colin Gray; Daniel Zicha; David P. Kelsell
The epidermis expresses a number of connexin (Cx) proteins that are implicated in gap junction-mediated cell communication. Distinct dominantly inherited mutations in Cx31 cause the skin disease erythrokeratoderma variabilis (EKV) and hearing loss with or without neuropathy. Functional studies reveal tissue-specific effects of these Cx31 disease-associated mutations. The Cx31 mutants (R42P)Cx31, (C86S)Cx31 and (G12D)Cx31 are associated with EKV and the mutant (66delD)Cx31 with peripheral neuropathy and hearing loss, however the mechanisms of pathogenesis remain to be elucidated. Expression of (R42P)Cx31, (C86S)Cx31 and (G12D)Cx31 in vitro, but not (WT)Cx31 or (66delD)Cx31, cause elevated levels of cell-type specific cell death. Previous studies suggest that Cx-associated cell death may be related to abnormal ‘leaky’ hemichannels but we produced direct evidence against that being the major mechanism. Additionally, our immunocytochemistry showed upregulation of components of the unfolded protein response (UPR) in cells expressing the EKV-associated Cx31 mutants but not (WT)Cx31 or (66delD)Cx31. We conclude that the endoplasmic reticulum (ER) stress leading to the UPR is the main mechanism of mutant Cx31-associated cell death. These results indicate that, in vivo, ER stress may lead to abnormal keratinocyte differentiation and hyperproliferation in EKV patient skin.
Journal of Investigative Dermatology | 2013
Claire A. Scott; Vincent Plagnol; Daniela Nitoiu; Philip Bland; Diana C. Blaydon; Catherine M.T. Chronnell; Daniel S. Poon; David Bourn; László Gárdos; Andrea Császár; Mariann Tihanyi; Malcolm H.A. Rustin; Nigel Burrows; Christopher Bennett; John I. Harper; Bernard Conrad; Ishwar C. Verma; Saleem M. Taibjee; Celia Moss; Edel A. O'Toole; David P. Kelsell
cated that MBTPS2 is mainly expressed in the upper granular layer in normal skin, as previously shown (Aten et al., 2010); however, in OS skin, MBTPS2 was expressed throughout the epidermis (Figure 2c). There was no apparent difference in MBTPS2 localization in the skin of a KFSD patient with the p.N508S mutation (Aten et al., 2010). It is unclear why this is but it may be because of differences in processing of the mutants in the two diseases. In summary, we demonstrate a novel association between an MBTPS2 mutation and an X-linked form of OS. This expands the number of disorders linked to MBTPS2 mutations and reveals clinical heterogeneity associated with different MBTPS2 mutations. Written, informed consent was obtained from all family members or their legal guardians. This study was approved by the South East NHS Research Ethics Committee and was performed according to the Declaration of Helsinki Principles.
Clinical and Experimental Dermatology | 2011
Claire A. Scott; Edel A. O’Toole; M. J. Mohungoo; Andrew G. Messenger; David P. Kelsell
Erythrokeratoderma variabilis (EKV) is characterized by fixed hyperkeratotic plaques and transient erythema. Mutations in the genes GJB3 and GJB4, which encode connexin (Cx)31 and Cx30.3, are associated with EKV. We report one novel mutation in Cx31 and one recurrent mutation in Cx30.3 in two different families. One novel rare sequence variant of unknown clinical significance was also identified. This finding extends the spectrum of known EKV‐associated mutations.
Genes | 2014
Thiviyani Maruthappu; Claire A. Scott; David P. Kelsell
The last decade has seen considerable advances in our understanding of the genetic basis of skin disease, as a consequence of high throughput sequencing technologies including next generation sequencing and whole exome sequencing. We have now determined the genes underlying several monogenic diseases, such as harlequin ichthyosis, Olmsted syndrome, and exfoliative ichthyosis, which have provided unique insights into the structure and function of the skin. In addition, through genome wide association studies we now have an understanding of how low penetrance variants contribute to inflammatory skin diseases such as psoriasis vulgaris and atopic dermatitis, and how they contribute to underlying pathophysiological disease processes. In this review we discuss strategies used to unravel the genes underlying both monogenic and complex trait skin diseases in the last 10 years and the implications on mechanistic studies, diagnostics, and therapeutics.
American Journal of Human Genetics | 2015
Zhimiao Lin; Jiahui Zhao; Daniela Nitoiu; Claire A. Scott; Vincent Plagnol; Frances J.D. Smith; Neil J. Wilson; Christian Cole; Mary E. Schwartz; W.H. Irwin McLean; Huijun Wang; Cheng Feng; Lina Duo; Eray Yihui Zhou; Yali Ren; Lanlan Dai; Yulan Chen; Jianguo Zhang; Xun Xu; Edel A. O’Toole; David P. Kelsell; Yong Yang
Calpastatin is an endogenous specific inhibitor of calpain, a calcium-dependent cysteine protease. Here we show that loss-of-function mutations in calpastatin (CAST) are the genetic causes of an autosomal-recessive condition characterized by generalized peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, which we propose to be given the acronym PLACK syndrome. In affected individuals with PLACK syndrome from three families of different ethnicities, we identified homozygous mutations (c.607dup, c.424A>T, and c.1750delG) in CAST, all of which were predicted to encode truncated proteins (p.Ile203Asnfs∗8, p.Lys142∗, and p.Val584Trpfs∗37). Immunohistochemistry shows that staining of calpastatin is reduced in skin from affected individuals. Transmission electron microscopy revealed widening of intercellular spaces with chromatin condensation and margination in the upper stratum spinosum in lesional skin, suggesting impaired intercellular adhesion as well as keratinocyte apoptosis. A significant increase of apoptotic keratinocytes was also observed in TUNEL assays. In vitro studies utilizing siRNA-mediated CAST knockdown revealed a role for calpastatin in keratinocyte adhesion. In summary, we describe PLACK syndrome, as a clinical entity of defective epidermal adhesion, caused by loss-of-function mutations in CAST.
Molecular Syndromology | 2016
Julio C. Salas-Alanis; Claire A. Scott; Óscar Raúl Fajardo-Ramírez; Carola Duran; María Guadalupe Moreno-Treviño; David P. Kelsell
GAPO syndrome is a very rare genetic disorder characterized by growth retardation, alopecia, pseudoanodontia and progressive optic atrophy (GAPO). To date, only 30 cases have been described worldwide. Recently, gene alterations in the ANTXR1 gene have been reported to be causative of this disorder, and an autosomal recessive pattern has been observed. This gene encodes a matrix-interacting protein that works as an adhesion molecule. In this report, we describe 2 homozygous siblings diagnosed with GAPO syndrome carrying a new missense mutation. This mutation produces the substitution of a glutamine in position 137 for a leucine (c.410A>T, p.Q137L).
Journal of Investigative Dermatology | 2018
M. Pigors; John E.A. Common; Xuan Fei Colin C. Wong; Sajid Malik; Claire A. Scott; Niloofar Tabarra; Herty Liany; Jianjun Liu; Vachiranee Limviphuvadh; Sebastian Maurer-Stroh; Mark Boon Yang Tang; Nicholas J. Lench; David J. Margolis; David A. van Heel; Charles A. Mein; Natalija Novak; Hansjörg Baurecht; Stephan Weidinger; W.H. Irwin McLean; Alan D. Irvine; Edel A. O’Toole; Michael A. Simpson; David P. Kelsell
M.P was supported by a Fellowship from the German Research Foundation (DFG). This work received infrastructure support through the DFG Cluster of Excellence “Inflammation at Interfaces” (grants EXC306 and EXC306/2), and was supported by grants (WE2678/6-1, WE2678/6-2, WE2678/9) from the DFG and the e:Med sysINFLAME grant no. 01ZX1306A from the German Federal Ministry of Education and Research (BMBF). J.E.A.C. and X.F.C.C.W. are funded by A*STAR SPF funding for translational skin research and genetic orphan diseases